Clinical Trial Update: A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of modified release formulations of GSK2982772 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Disease

Drugs mentioned

• GSK2982772 (GSK2982772)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Autoimmune Diseases | Phase 1 | Status: COMPLETED | Results posted: 2020-05-01